Health-related quality of life and symptoms of chronic myeloid
leukemia patients after discontinuation of tyrosine kinase
inhibitors: results from the EURO-SKI Trial

J 2024

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

EFFICACE, Fabio, Francois-Xavier MAHON, Johan RICHTER, Alfonso PICIOCCHI, Marta CIPRIANI et. al.

Basic information

Original name

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Authors

EFFICACE, Fabio, Francois-Xavier MAHON, Johan RICHTER, Alfonso PICIOCCHI, Marta CIPRIANI, Franck E NICOLINI, Jiří MAYER (203 Czech Republic, belonging to the institution), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Jeroen J W M JANSSEN, Panayiotis PANAYIOTIDIS, Hanne VESTERGAARD, Perttu KOSKENVESA, Antonio ALMEIDA, Henrik HJORTH-HANSEN, Joaquin MARTINEZ-LOPEZ, Ulla OLSSON-STROMBERG, Andreas HOCHHAUS, Marc G BERGER, Gabriel ETIENNE, Hana KLAMOVA, Edgar FABER, Philippe ROUSSELOT, Markus PFIRRMANN and Susanne SAUSSELE

Edition

Leukemia, London, Nature Publishing Group, 2024, 0887-6924

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 11.400 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1038/s41375-024-02341-4

UT WoS

001268749100001

Keywords in English

chronic myeloid leukemia

Abstract

V originále

Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients who had been on tyrosine kinase inhibitors (TKIs) therapy for at least 3 years and achieved MR4 for at least 1 year were enrolled from 11 European countries, and the EORTC QLQ-C30 and the FACIT-Fatigue questionnaires were used to assess HRQoL and fatigue respectively. Patients were categorized into the following age groups: 18-39, 40-59, 60-69 and >= 70 years. Of 728 patients evaluated at baseline, 686 (94%) completed HRQoL assessments. The median age at TKI discontinuation was 60 years. Our findings indicate that HRQoL and symptom trajectories may vary depending on specific age groups, with younger patients benefiting the most. Improvements in patients aged 60 years or older were marginal across several HRQoL and symptom domains. At the time of considering TKI discontinuation, physicians could inform younger patients that they may expect valuable HRQoL benefits. Considering the marginal improvements observed in patients aged 60 years or above, it may be important to further investigate the value of TFR compared to a lowest effective dose approach in this older group of patients.

Links

LX22NPO5102, research and development project

Name: Národní ústav pro výzkum rakoviny (Acronym: NÚVR)

Investor: Ministry of Education, Youth and Sports of the CR, National institute for cancer research, 5.1 EXCELES

Citovat

EFFICACE, Fabio, Francois-Xavier MAHON, Johan RICHTER, Alfonso PICIOCCHI, Marta CIPRIANI, Franck E NICOLINI, Jiří MAYER, Daniela ŽÁČKOVÁ, Jeroen J W M JANSSEN, Panayiotis PANAYIOTIDIS, Hanne VESTERGAARD, Perttu KOSKENVESA, Antonio ALMEIDA, Henrik HJORTH-HANSEN, Joaquin MARTINEZ-LOPEZ, Ulla OLSSON-STROMBERG, Andreas HOCHHAUS, Marc G BERGER, Gabriel ETIENNE, Hana KLAMOVA, Edgar FABER, Philippe ROUSSELOT, Markus PFIRRMANN and Susanne SAUSSELE. Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial. Leukemia. London: Nature Publishing Group, 2024, vol. 38, No 8, p. 1722-1730. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-024-02341-4.

@article{2421678,
   author = {Efficace, Fabio and Mahon, FrancoisandXavier and Richter, Johan and Piciocchi, Alfonso and Cipriani, Marta and Nicolini, Franck E and Mayer, Jiří and Žáčková, Daniela and Janssen, Jeroen J W M and Panayiotidis, Panayiotis and Vestergaard, Hanne and Koskenvesa, Perttu and Almeida, Antonio and HjorthandHansen, Henrik and MartinezandLopez, Joaquin and OlssonandStromberg, Ulla and Hochhaus, Andreas and Berger, Marc G and Etienne, Gabriel and Klamova, Hana and Faber, Edgar and Rousselot, Philippe and Pfirrmann, Markus and Saussele, Susanne},
   article_location = {London},
   article_number = {8},
   doi = {http://dx.doi.org/10.1038/s41375-024-02341-4},
   keywords = {chronic myeloid leukemia},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial},
   url = {https://www.nature.com/articles/s41375-024-02341-4},
   volume = {38},
   year = {2024}
}

TY  - JOUR
ID  - 2421678
AU  - Efficace, Fabio - Mahon, Francois-Xavier - Richter, Johan - Piciocchi, Alfonso - Cipriani, Marta - Nicolini, Franck E - Mayer, Jiří - Žáčková, Daniela - Janssen, Jeroen J W M - Panayiotidis, Panayiotis - Vestergaard, Hanne - Koskenvesa, Perttu - Almeida, Antonio - Hjorth-Hansen, Henrik - Martinez-Lopez, Joaquin - Olsson-Stromberg, Ulla - Hochhaus, Andreas - Berger, Marc G - Etienne, Gabriel - Klamova, Hana - Faber, Edgar - Rousselot, Philippe - Pfirrmann, Markus - Saussele, Susanne
PY  - 2024
TI  - Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
JF  - Leukemia
VL  - 38
IS  - 8
SP  - 1722-1730
EP  - 1722-1730
PB  - Nature Publishing Group
SN  - 08876924
KW  - chronic myeloid leukemia
UR  - https://www.nature.com/articles/s41375-024-02341-4
N2  - Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients who had been on tyrosine kinase inhibitors (TKIs) therapy for at least 3 years and achieved MR4 for at least 1 year were enrolled from 11 European countries, and the EORTC QLQ-C30 and the FACIT-Fatigue questionnaires were used to assess HRQoL and fatigue respectively. Patients were categorized into the following age groups: 18-39, 40-59, 60-69 and >= 70 years. Of 728 patients evaluated at baseline, 686 (94%) completed HRQoL assessments. The median age at TKI discontinuation was 60 years. Our findings indicate that HRQoL and symptom trajectories may vary depending on specific age groups, with younger patients benefiting the most. Improvements in patients aged 60 years or older were marginal across several HRQoL and symptom domains. At the time of considering TKI discontinuation, physicians could inform younger patients that they may expect valuable HRQoL benefits. Considering the marginal improvements observed in patients aged 60 years or above, it may be important to further investigate the value of TFR compared to a lowest effective dose approach in this older group of patients.
ER  -

EFFICACE, Fabio, Francois-Xavier MAHON, Johan RICHTER, Alfonso PICIOCCHI, Marta CIPRIANI, Franck E NICOLINI, Jiří MAYER, Daniela ŽÁČKOVÁ, Jeroen J W M JANSSEN, Panayiotis PANAYIOTIDIS, Hanne VESTERGAARD, Perttu KOSKENVESA, Antonio ALMEIDA, Henrik HJORTH-HANSEN, Joaquin MARTINEZ-LOPEZ, Ulla OLSSON-STROMBERG, Andreas HOCHHAUS, Marc G BERGER, Gabriel ETIENNE, Hana KLAMOVA, Edgar FABER, Philippe ROUSSELOT, Markus PFIRRMANN and Susanne SAUSSELE. Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial. \textit{Leukemia}. London: Nature Publishing Group, 2024, vol.~38, No~8, p.~1722-1730. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/s41375-024-02341-4.

Detailed Information on Publication Record